Option chain shows key data for Allarity Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Allarity Therapeutics.

Allarity Therapeutics (NASDAQ:ALLR) Stock, Option Chain

Allarity Therapeutics

Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.

Chi sale e chi scende: i maggiori movimenti nel pre-market di oggi

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ALLR

EFSH

FRGT

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MYNA

OMEX

PGNY

SGLY

SMSI

TBIO

VEEA

VERO

WBUY

XCUR

Why Exicure Shares Are Trading Higher By Around 180%; Here Are 20 Stocks Moving Premarket

movers image

ADGM

APVO

AVGR

BBLG

CNEY

DRMA

GDHG

GLMD

HCWC

INTC

NCPL

NKGN

OPTT

SPRC

TNON

WHLR

ZVSA

Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket

xr:d:DAFhS-kD63I:2,j:45998648077,t:23042711

Intraday Update

ALGM

ALKS

ATCH

ATPC

AZTR

BLCO

CJET

CONN

CREV

ENPH

FLEX

GERN

GOOGL

KARO

KORE

LITM

MANH

NAAS

NIVF

NUWE

NUZE

Next Technology Holding Inc. - Ordinary Shares

NXTT

PIRS

ROKU

SAGE

SGMO

SLNA

SOAR

SYNX

TKNO

TSLA

ULTA

VSTM

Vintage Wine Estates, Inc. - Common Stock

WFRD

Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics Inc

Allreal Holding Ltd

<ul>
<li>Digitally enabled comparable sales growth was 30.0%, reflecting two-year stacked comp growth of 47.0%</li>
<li>Membership fee income increased by 8.4% year-over-year to $115.0 million</li>
</ul>

Earnings

Retail Sales

General

BJ's Wholesale Club Q3 Comparable Club Sales Increased By 1.5% YoY, Comparable Club Sales, Excluding Gasoline Sales, Increased By 3.8% YoY, Led By Strong Traffic

Barclays analyst Brian Morton upgrades Bank of Nova Scotia (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BNS#TSX">BNS</a>) from Underweight to Equal-Weight and raises the price target from C$70 to C$81.

Upgrades

Price Target

Analyst Ratings

TSX:BNS

Barclays Upgrades Bank of Nova Scotia to Equal-Weight, Raises Price Target to C$81

NVIDIA Corp&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) experienced a 2.36% decline in pre-market trading on Thursday, as per <a href="https://pro.benzinga.com">Benzinga Pro,</a> despite surpassing Wall Street expectations in its third-quarter earnings. 
What Happened:&nbsp;The chipmaker reported a 94% year-over-year increase in revenue, reaching $35.1 billion, exceeding the anticipated $33.12 billion. Additionally, the company&#8217;s earnings per share were 81 cents, surpassing the projected 75 cents.
Despite these strong financial results, investor concerns arose due to a slowdown in sales compared to previous quarters.&nbsp;Derren Nathan,&nbsp;head of equity research at&nbsp;Hargreaves Lansdown, <a href="https://www.cnbc.com/2024/11/21/nvidia-nvda-stock-slumps-despite-q3-earnings-beat.html">told</a>&nbsp;CNBC&nbsp;that the drop in NVIDIA&#8217;s stock price suggests that &#8220;even&nbsp;outstanding isn't enough for some&nbsp;investors.&#8221;
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42102652/michael-saylors-microstrategy-takes-wall-street-by-storm-becomes-second-most-traded-stock-after-nvidia?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Michael Saylor&#8217;s MicroStrategy Takes Wall Street By Storm, Becomes Second-Most Traded Stock After Nvidia</a>
Why It Matters: This also comes at a time when <a href="https://www.benzinga.com/news/large-cap/24/11/42094649/nvidia-stock-historically-drops-in-december-after-q3-earnings">seasonal statistics have revealed </a>that December has historically been a challenging month for Nvidia investors. The semiconductor giant of Jensen Huang often enters a temporary bearish phase following its third-quarter earnings report. Historical data indicates that while NVIDIA frequently delivers positive third-quarter earnings, December tends to be a negative month for its stock.
Meanwhile, Wedbush Securities Managing Director Dan Ives <a href="https://www.benzinga.com/markets/equities/24/11/42102642/nvidia-delivered-jaw-dropping-q3-earnings-says-dan-ives-this-is-the-fourth-revolution-playing-out-in-front-of-our-eyes">described the results as a "jaw-dropper," </a>emphasizing the transformative potential of the company's AI technology. "This is the fourth revolution playing out in front of our eyes," Ives told CNN, <a href="https://x.com/jchatterleyCNN/status/1859386289315053838" target="_blank" rel="noreferrer noopener">highlighting</a> the broader implications for the tech sector.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/42079984/dogecoin-bitcoin-left-in-the-dust-by-ai-meme-coin-goat-as-nvidias-q3-earnings-draw-near?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Dogecoin, Bitcoin Left In The Dust By AI Meme Coin GOAT As Nvidia&#8217;s Q3 Earnings Draw Near</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

NVDA

Nvidia Slides During Thursday Pre-Market Despite Beating Q3 Estimates: 'Even Outstanding Isn't Enough For Some Investors'

"The innovative research that will be presented at this year's ASH highlights our robust clinical development program and our commitment to exploring novel modalities and therapeutic targets, as we work to improve outcomes and address unmet needs for people with hematologic neoplasms and malignancies," said Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories.&nbsp;

Merck To Present New Data For Approved And Investigational Medicines Across Multiple Hematologic Malignancies At ASH Annual Meeting From Dec. 7-10

BJ's Wholesale Club (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) reported quarterly earnings of $1.18 per share which beat the analyst consensus estimate of $0.91 by 29.67 percent. The company reported quarterly sales of $5.10 billion which met the analyst consensus estimate. This is a 3.55 percent increase over sales of $4.92 billion the same period last year.

BJ's Wholesale Club Q3 2024 Adj EPS $1.18 Beats $0.91 Estimate, Sales $5.10B Inline

Needham analyst Matt Dezort maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Buy and raises the price target from $385 to $450.

PANW

Needham Maintains Buy on Palo Alto Networks, Raises Price Target to $450

Uber Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) reportedly plans to <a href="https://www.benzinga.com/news/24/08/40625596/uber-pumps-capital-into-nvidia-backed-wayves-series-c-funding-round">invest in autonomous driving firm</a> Pony AI&#8216;s initial public offering in the U.S.
What Happened: Uber is looking to buy over $10 million of shares in the IPO, Bloomberg <a href="https://www.bloomberg.com/news/articles/2024-11-21/uber-said-to-be-in-talks-to-invest-in-us-ipo-of-china-s-pony-ai?srnd=homepage-canada">reported</a>, citing people familiar with the matter. However, the investment size has not been finalized and talks are ongoing, the report added.
Uber may also consider a partnership with Pony AI for its self-driving technology outside the U.S., one of the sources told Bloomberg. 
Though Pony AI&#8217;s IPO was initially expected to be priced on Thursday, it is now expected to be priced next week to give the company time to address questions from regulators. The company will issue 20 million American depository shares raising as much as $260 million, according <a href="https://www.sec.gov/Archives/edgar/data/1969302/000110465924120872/tm2310344-28_fwp.htm">to</a> a regulatory filing.
Why It Matters: Pony AI was founded in late 2016 by James Peng and Tiancheng Lou. It operates self-driving fleets in the U.S. and China and has driven nearly 40 million autonomous testing and operation kilometers on open roads worldwide. 
Uber, meanwhile, has <a href="https://www.benzinga.com/markets/equities/24/09/40855784/uber-stock-spikes-as-ceo-praises-waymos-fully-autonomous-trips">partnerships with other autonomous vehicle companies</a> including Alphabet Inc.&#8217;s Waymo and UK&#8217;s Wayve.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42058338/byd-makes-a-million-nevs-in-less-than-2-months" target="_blank" rel="noreferrer noopener">BYD Makes A Million NEVs In Less Than 2 Months After Beating Tesla For The First Time Since 2022 In Quarterly Revenue</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

Media

UBER

Uber Could Pick Up $10M Stake In Chinese Autonomous Driving Firm Pony AI's US IPO: Report

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>) with a Buy and maintains $7 price target.

Reiteration

PYXS

HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target

On Wednesday, November 20, U.S. markets closed mixed. The Nasdaq slipped, weighed down by geopolitical tensions and Target&#8217;s disappointing performance. Nvidia declined ahead of earnings, which later underwhelmed. Meanwhile, the Dow edged higher, and the S&amp;P 500 remained flat.
In economic data, U.S. mortgage applications increased by 1.7% for the week ending November 15, up from the 0.5% rise recorded the previous week.
Healthcare, energy, and materials led S&amp;P 500 gains Wednesday, while consumer discretionary and financials declined.
The Dow Jones Industrial Average was up 0.32% and closed at 43,408.47, the S&amp;P 500 gained 0.002% to 5,917.11, and the Nasdaq Composite declined 0.11% to finish at 18,966.14.
Asia Markets Today
<ul>
<li>On Thursday, Japan&#8217;s Nikkei 225 declined 0.97% and ended the session at 38,002.50, led by losses in the Insurance, Transportation Equipment, and Power sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 fell 0.04% and ended the day at 8,323.00, led by losses in the Consumer Discretionary, Consumer Staples, and A-REITs sectors.</li>
<li>India&#8217;s Nifty 50 declined 0.73% to 23,346.70, and Nifty 500 slid 0.85% closing at 21,816.45, led by losses in the Public Sector Undertakings, Oil &amp; Gas and Power sectors.</li>
<li>China&#8217;s Shanghai Composite gained 0.07% to close at 3,370.40, and the Shenzhen CSI 300 rose 0.09%, finishing the day at 3,989.30.</li>
<li>Hong Kong&#8217;s Hang Seng fell 0.53% and closed the session at 19,601.11.</li>
</ul>
Eurozone at 05:30 AM ET
<ul>
<li>The European STOXX 50 index was down 0.36%.</li>
<li>Germany&#8217;s DAX slid 0.02%.</li>
<li>France&#8217;s CAC declined 0.43%.</li>
<li>FTSE 100 index traded higher by 0.20%</li>
</ul>
Commodities at 05:30 AM ET
<ul>
<li>Crude Oil WTI was trading higher by 1.70% at $69.94/bbl, and Brent was up 1.58% at $73.95/bbl.</li>
<li>Oil prices rose amid escalating Russia-Ukraine missile strikes, overshadowing a larger-than-expected U.S. crude inventory increase.</li>
<li>Natural Gas rose 6.45% to $3.297.</li>
<li>Gold was trading higher by 0.78% at $2,672.45, Silver was up 0.35% to $31.115, and Copper fell 0.83% to $4.1210.</li>
</ul>
U.S. Futures at 05:30 AM ET
Dow futures declined 0.07%, S&amp;P 500 futures were down 0.24% and Nasdaq 100 futures fell 0.35%.
Forex at 05:30 AM ET
The U.S. dollar index gained 0.04% to 106.72, the USD/JPY was down 0.64% to 154.44, and the USD/AUD slid 0.08% to 1.5357.
Photo by Pavel Bobrovskiy via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia And Europe Markets Mixed; Dollar Hovers Near 52-Week High - Global Markets Today While US Slept

Throughout this NFL-style, three-day combine, prospects from nearly every state are expected to attend, with this year's event expected to host the largest total number of recruits in the event's history and the largest combine-style event in the country.
In connection with their participation in the event, all student-athletes will receive a complimentary one-month trial of the Signing Day Sports app, enhancing their visibility to college recruiters.
By collecting registration fees and offering exclusive apparel for participants and fans, the combine enables the Company to drive immediate income while strengthening its brand presence.&nbsp;
&nbsp;

Signing Day Sports Provides Update On Upcoming 3rd Annual US Army Bowl National Combine; Says Combine Enables Company To Drive Immediate Income While Strengthening Its Brand Presence

China Renaissance analyst Yiwen Zhang downgrades Grab Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) from Buy to Hold and announces $5.4 price target.

Downgrades

GRAB

China Renaissance Downgrades Grab Holdings to Hold, Announces $5.4 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Lisata Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTA#NASDAQ">LSTA</a>) with a Buy and maintains $15 price target.

LSTA

HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target

Needham analyst Mike Cikos maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Buy and raises the price target from $160 to $200.

SNOW

Needham Maintains Buy on Snowflake, Raises Price Target to $200

<ul>
<li>Aphexda is Biolinerx's FDA-Approved Stem Cell Mobilization Agent Indicated In Combination With Filgrastim For Collection And Subsequent Autologous Transplantation In Patients With Multiple Myeloma.</li>
<li>BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% to 23%.</li>
<li>BioLineRx retains rights to develop and commercialize motixafortide in solid tumors, including PDAC.</li>
<li>BioLineRx received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC to support company's pipeline and expansion.</li>
<li>Transactions enable significant reduction in BioLineRx's operational expenses and debt, and allow the company to focus on development activities in areas of high unmet need in oncology and rare diseases –</li>
</ul>

Biotech

Health Care

Contracts

BLRX

BioLineRx And Ayrmid Entered Into A License Agreement For Motixafortide (Commercially Sold In The US As Aphexda), BioLineRx Will Receive A $10M Upfront Payment And Is Also Eligible To Receive Up To An Additional $87M Of Potential Commercial Milestones, Plus Royalties Between 18%-23% On Net Sales Of Aphexda

Trimble will provide fleet management and telematics solutions to vehicles across PFG's three business segments including Performance Foodservice Core-Mark and Vistar.&nbsp;
All PFG vehicles will be equipped with Trimble Instinct, Trimble's in-cab ecosystem that seamlessly connects drivers and back-office staff to boost safety, compliance and efficiency.
 &nbsp;

PFGC

TRMB

Performance Food Group Selects Trimble As Its Premier Fleet Management Provider; Migrates 100% Of Its Fleet Management Business To Trimble Instinct, Doubling Trimble-Serviced Trucks To Over 8,000

Citigourp Global Markets 2% Protected Notes Linked To The Djia

PDD Holdings Q3 Adj EPADS $2.65 Misses $2.82 Estimate, Sales $14.16B Miss $14.47B Estimate

Artificial intelligence (AI) darling Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) <a href="https://www.benzinga.com/news/earnings/24/11/42099904/nvidia-beats-q3-revenue-eps-estimates-supply-constraints-ding-stock-huang-says-age-of-ai-is-in-full-steam">beat expectations yet again</a> with impressive third-quarter revenue and earnings reported after Wednesday's market close. 
What happened: The world's most valuable company <a href="https://www.benzinga.com/24/11/42099904/nvidia-q3-earnings-highlights">disclosed </a>third-quarter revenue of $35.1 billion and earnings per share of 81 cents, both beating analysts' estimates.&nbsp;
The Jensen Huang-led firm has had a blockbuster run on equity markets in the last few years, multiplying investors' money by orders of magnitude.&nbsp;
Indeed, Nvidia shares have exploded by 2,718% in the last five years, outperforming all well-known companies on Wall Street.
In comparison, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)—the world's most valued cryptocurrency exerting a similar influence on the digital assets market—grew 1,171% over the last five years.
See Also: <a href="https://www.benzinga.com/24/11/42079799/microstrategys-michael-saylor-to-advocate-for-bitcoin-investment-at-microsoft-board-meeting-offers-to-educate-rumble-ceo-with-the-strategy">Microstrategy&#8217;s Michael Saylor To Advocate For Bitcoin At Microsoft Board Meeting, Offers To Educate Rumble CEO As Well</a>
<h2 class="wp-block-heading">Which Is Offering Better Returns Relative To Risk?</h2>
Both Nvidia and Bitcoin are risk-laden investments, and traders must navigate their inherent volatility to profit.
To get a more accurate picture, analysts track the Sharpe Ratio, a measure of risk-adjusted returns. 
For Bitcoin, this ratio stood at -5 as of this writing, <a href="https://in.tradingview.com/chart/XlzxagWe/?symbol=BITSTAMP%3ABTCUSD">per </a>TradingView, implying that the expected return was lower than that of a risk-free investment, such as a Treasury yield.&nbsp;
On the other hand, Nvidia <a href="https://www.tradingview.com/chart/XlzxagWe/?symbol=NASDAQ%3ANVDA">showed </a>a Sharpe ratio of 0.69, indicating that investment in the stock was generating positive returns above the risk-free rate.
<h2 class="wp-block-heading">Are Their Valuations Inflated?</h2>
Another metric to compare the two hot financial assets was whether they were expensive or cheap relative to their fundamentals.
For stocks, this is typically measured by the price-to-earnings ratio, or simply the P/E ratio.&nbsp;
Nvidia's P/E ratio showed a reading of 73.478 per TradingView, suggesting that the stock was highly overpriced. It could also imply that investors expect the company to have stronger performance and higher earnings in the future.
The P/E counterpart for Bitcoin is the network value to transactions ratio or NVT ratio.
According to on-chain analytics firm <a href="https://cryptoquant.com/asset/btc/chart/network-indicator/nvt-ratio?window=DAY&amp;sma=0&amp;ema=0_30&amp;priceScale=log&amp;metricScale=log&amp;chartStyle=column">CryptoQuant</a>, the 30-day EMA of Bitcoin's NVT was at 28.28 at the time of writing, a decline from 36.32 recorded at the beginning of the month.
The decline implied that transaction volume was outperforming market growth or that valuation had dropped without any change in transaction activity.
Price Action: At the time of writing, Bitcoin was trading at $97,396.60, rising 4.97% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. Shares of Nvidia were down 2.49% in after-hours trading.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/42079984/dogecoin-bitcoin-left-in-the-dust-by-ai-meme-coin-goat-as-nvidias-q3-earnings-draw-near">Dogecoin, Bitcoin Left In The Dust By AI Meme Coin GOAT As Nvidia&#8217;s Q3 Earnings Draw Near</a></li>
</ul>
Photos courtesy: Nvidia and Pixabay

$BTC

Nvidia Vs. Bitcoin: Jensen Huang-Led Chip Giant's Stock Outperformed The Top Cryptocurrency Over 5 Years. Here's How They Compare On Other Metrics

Benchmark analyst Cody Acree maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Buy and raises the price target from $170 to $190.

Benchmark Maintains Buy on NVIDIA, Raises Price Target to $190

Roth MKM analyst Joe Reagor initiates coverage on Stardust Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) with a Buy rating and announces Price Target of $13.

Initiation

SDST

Roth MKM Initiates Coverage On Stardust Power with Buy Rating, Announces Price Target of $13

Morgan Stanley analyst James Faucette upgrades Evertec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTC#NYSE">EVTC</a>) from Underweight to Equal-Weight and raises the price target from $33 to $35.

EVTC

Morgan Stanley Upgrades Evertec to Equal-Weight, Raises Price Target to $35

Warning: ALLR is at high risk of performing badly

"This quarter's progress marks a steady period of advancement for Allarity (ALLR) as we have maintained a strong cash position, achieved record pat...

Allarity reports Q3 EPS ($7.71)

Allarity Therapeutics GAAP EPS of -$7.71 beats by $0.69

Allarity (ALLR) Therapeutics provided a corporate update highlighting three significant developments: extended treatment duration for patients in i...

Allarity reports progress in Phase 2 stenoparib trial

Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity Therapeutics, Inc. Inc. of Class Action Lawsuit and Upcoming Deadlines – ALLR

Press Releases

ALLR Deadline: Rosen Law Firm Urges Allarity Therapeutics, Inc. (NASDAQ: ALLR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Legal

ALLR DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALLR

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity Therapeutics, Inc. Inc. of Class Action Lawsuit and Upcoming Deadlines - ALLR

Penny Stocks

ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

DEADLINE ALERT for ALLR, and COIN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

COIN

ABVC BioPharma

Comments

Allarity Therapeutics

Allarity Therapeutics (ALLR) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga